Clinical & Translational Immunology

Papers
(The TQCC of Clinical & Translational Immunology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
43
39
The spectrum of B cells in the pathogenesis, diagnosis and therapeutic applications of immunoglobulin G4‐related disease28
Polyfunctional T peripheral helper cells are associated with the magnitude and durability of antibody responses after COVID‐1928
SARS‐CoV‐2‐associated T‐cell infiltration in the central nervous system25
Characteristics of PD‐1+CD4+ T cells in peripheral blood and synovium of rheumatoid arthritis patients23
Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis23
Circulating cytokine and chemokine patterns associated with cytomegalovirus reactivation after stem cell transplantation22
Biomarkers to predict and diagnose pulmonary complications in children post haematopoietic stem cell transplant20
An optimised whole blood interleukin‐2 release assay is more sensitive than interferon‐γ ELIS pot for detecting and quantifying gluten‐specific 19
Spatial omics for profiling the dynamic tumor microenvironment17
15
Targeting BMI‐1 to deplete antibody‐secreting cells in autoimmunity14
14
Adeno‐associated viral vectors encoding anti‐P2X7 nanobodies reduce graft‐versus‐host disease in a humanised mouse model14
14
Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma13
Effects of extremely preterm birth on cytokine and chemokine responses induced by T‐cell activation during infancy13
Mass cytometry analysis reveals altered immune profiles in patients with coronary artery disease12
Naturally acquired adaptive immunity to Streptococcus pneumoniae is impaired in rheumatoid arthritis patients11
The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation11
Inhibitory effect of hydroxychloroquine on glucocorticoid‐induced osteoporosis in lupus therapy10
10
Immunological insights into gastric polyps: pathogenesis, inflammation and neoplastic potential10
Optimised modular anti‐FLAG CAR T cells for solid tumor therapy10
Adaptive immune response to the autoantigen LL ‐37 differentiates atherosclerotic cardiovascular disease phenotypes10
Genome‐wide association study and polygenic risk scores of eosinophilia in Taiwan10
Siglec‐1, an easy and contributory inflammation marker in rheumatology9
9
High KRT17 expression in tumour budding indicates immunologically ‘hot’ tumour budding and predicts good survival in patients with colorectal cancer9
9
Robust immunity to influenza vaccination in haematopoietic stem cell transplant recipients following reconstitution of humoral and adaptive immunity9
Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models9
9
Data standards for single‐cell RNA ‐sequencing of paediatric cancer8
8
CD39 expression defines exhausted CD4+ T cells associated with poor survival and immune evasion in human gastric cancer8
Skin immunity and inflammation: cellular interactions and communication8
8
Human axillary lymph node T follicular helper (Tfh) and Precursor‐Tfh cells exhibit functional flexibility following seasonal influenza vaccination8
Alterations of circulating innate lymphoid cells in recent‐onset type 1 diabetes8
Helminths as architects of trained tolerance: implications for human health7
Prediction of intravenous immunoglobulin retreatment in children with Kawasaki disease using models combining lymphocyte subset and cytokine profile in an East Asian cohort7
A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies7
Serological responses and clinical outcomes following a three‐dose primary COVID‐19 vaccine schedule in kidney transplant recipients and people on dialysis6
Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival6
Hypoxia‐inducible factor‐1α regulates the interleukin‐6 production by B cells in rheumatoid arthritis6
A unique cytotoxic CD4 + T cell‐signature defines critical COVID‐196
Neutralising antibody responses to emerging SARSCoV ‐2 omicron sub‐variants are enhanced in per6
Infiltrating characteristics and prognostic value of tertiary lymphoid structures in resected gastric neuroendocrine neoplasm patients6
A novel case of autosomal recessive CARD11 loss‐of‐function underlying impaired antiviral immunity and a review of literature6
6
Pulmonary complications post allogeneic haematopoietic stem cell transplant in children6
6
A comprehensive analysis of the correlation between plasma cytokines/chemokines and tumor immune microenvironment signature influences the response of checkpoint inhibitors in advanced non‐small‐cell 6
6
Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosis6
The impact of B‐cell reconstitution on mRNA vaccine responses in allogeneic stem cell transplant recipients6
Fatty acid metabolism—an emerging regulatory node in T‐cell immunometabolism6
Long‐term effects of influenza and Bacille Calmette–Guérin vaccination on systemic inflammation5
Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis5
Elucidating novel immune profiles for predicting infection in high‐risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia5
Multi‐omics integration reveals a nonlinear signature that precedes progression of lung fibrosis5
Genetic differences in the HLA region contribute to the variability in SARS‐CoV‐2 vaccine responsiveness of older persons: the Doetinchem Cohort Study5
Adoptive T‐cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosis5
Effect of Bacille Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2 and COVID‐19 vaccination5
0.14344382286072